Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

114.51 +1.33 (+1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
62 63 Next >
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
From Gilead Sciences, Inc.
Via Business Wire
American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. (NASDAQ: GILD) is a very defensive, steady growth play. 
Via Benzinga
2 Magnificent Dividend Stocks to Buy Before the Next Recession
The healthcare sector is a good place to find recession-proof stocks. 
Via The Motley Fool
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
Via Investor Brand Network
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,300 Today
 
Via Benzinga
Expert Ratings for Gilead Sciences
 
Via Benzinga
Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger
The company sells Trodelvy and two cell therapies. Sales of all three surged. 
Via Investor's Business Daily
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years
Should you buy Gilead Sciences stock despite its poor track record? 
Via The Motley Fool
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
P/E Ratio Insights for Gilead Sciences
 
Via Benzinga
What Does Gilead Sciences' Debt Look Like?
 
Via Benzinga
Better Buy: Pfizer vs. Gilead
Pfizer and Gilead look cheap right now. 
Via The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today
 
Via Benzinga
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits
Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help... 
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Gilead Sciences Announces First Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
6 Best Healthcare Stocks to Buy Right Now
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat. 
Via MarketBeat
Topics Economy Intellectual Property
3 Cash-Rich Biotech Stocks to Bet on for the Long Haul
Cash rich biotech stocks can survive while most of their peers struggle with rising interest rates. Here are three to watch. 
Via InvestorPlace
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
2 Excellent Dividend Stocks to Buy for Less Than $100
Both companies are steals at current levels. 
Via The Motley Fool
Berkshire Hathaway, Gilead Sciences, Vertex Pharmaceuticals And A Break-Out Casino Stock Feature On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. 
Via Benzinga
Strong Quant Screens Say These 7 Growth Stocks Are a Buy
StockRover’s quant screen is a grading system that brings up rewarding growth stocks to buy for income investors. 
Via InvestorPlace
Gamida Cell Stock Jumps Over 100% on FDA Approval
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo 
Via MarketBeat
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations
From Gilead Sciences, Inc.
Via Business Wire
3 Dividend Stocks to Buy and Hold for the Next Decade
Long-term investors looking for income should especially like these stocks. 
Via The Motley Fool
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.